IQVIA HOLDINGS INC.

(IQV)
  Report
Delayed Nyse  -  04:03 2022-08-08 pm EDT
233.66 USD   -0.46%
12:57pGlaxoSmithKline, IQVIA Introduce Vaccination Data Tracker
MT
07/29IQVIA HOLDINGS INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/29IQVIA Holdings Inc. Announces Executive Changes
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

KeyBanc Adjusts IQVIA Holdings' Price Target to $250 from $290, Keeps Overweight Rating

04/28/2022 | 10:40am EDT


© MT Newswires 2022
All news about IQVIA HOLDINGS INC.
12:57pGlaxoSmithKline, IQVIA Introduce Vaccination Data Tracker
MT
07/29IQVIA HOLDINGS INC. : Change in Directors or Principal Officers (form 8-K)
AQ
07/29IQVIA Holdings Inc. Announces Executive Changes
CI
07/27Dr. Reddy's Launches Generic Version of Myeloma Drug Velcade in US
MT
07/26China Accepts Sihuan Pharmaceutical Unit's Marketing for Breast Cancer Injection
MT
07/22IQVIA HOLDINGS INC. Management's Discussion and Analysis of Financial Condition and Re..
AQ
07/22Barclays Adjusts Price Target on IQVIA Holdings to $255 from $236, Keeps Overweight Rat..
MT
07/22Morgan Stanley Adjusts IQVIA Holdings' Price Target to $260 from $255, Keeps Overweight..
MT
07/21IQVIA : Reports Second-Quarter 2022 Results - Form 8-K
PU
07/21TRANSCRIPT : IQVIA Holdings Inc., Q2 2022 Earnings Call, Jul 21, 2022
CI
More news
Analyst Recommendations on IQVIA HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2022 14 514 M - -
Net income 2022 1 220 M - -
Net Debt 2022 10 874 M - -
P/E ratio 2022 36,7x
Yield 2022 -
Capitalization 43 579 M 43 579 M -
EV / Sales 2022 3,75x
EV / Sales 2023 3,41x
Nbr of Employees 83 000
Free-Float 72,2%
Chart IQVIA HOLDINGS INC.
Duration : Period :
Iqvia Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 20
Last Close Price 233,66 $
Average target price 266,78 $
Spread / Average Target 14,2%
EPS Revisions
Managers and Directors
Ari Bousbib Chairman, President & Chief Executive Officer
Ronald Earl Bruehlman Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
Jeffrey A. Spaeder Chief Medical & Scientific Officer
Costa Panagos President-Research & Development Solutions
Sector and Competitors
1st jan.Capi. (M$)
IQVIA HOLDINGS INC.-16.80%43 781
MODERNA, INC.-26.44%73 092
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235
CELLTRION, INC.2.78%20 815